TNDM icon

Tandem Diabetes Care

37.00 USD
+0.39
1.07%
At close Dec 24, 4:00 PM EST
Pre-market
36.99
-0.01
0.03%
1 day
1.07%
5 days
8.09%
1 month
21.63%
3 months
-18.57%
6 months
-7.45%
Year to date
30.60%
1 year
19.24%
5 years
-39.77%
10 years
-71.49%
 

About: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Employees: 2,400

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,272% more call options, than puts

Call options by funds: $145M | Put options by funds: $10.5M

150% more funds holding in top 10

Funds holding in top 10: 2 [Q2] → 5 (+3) [Q3]

26% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 46

4% more funds holding

Funds holding: 315 [Q2] → 327 (+12) [Q3]

3% more capital invested

Capital invested by funds: $3.01B [Q2] → $3.1B (+$91.5M) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 109 | Existing positions reduced: 116

3.94% less ownership

Funds ownership: 115.51% [Q2] → 111.57% (-3.94%) [Q3]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$37
0%
upside
Avg. target
$50
35%
upside
High target
$65
76%
upside

8 analyst ratings

positive
75%
neutral
25%
negative
0%
Citigroup
Joanne Wuensch
57% 1-year accuracy
27 / 47 met price target
35%upside
$50
Buy
Maintained
11 Dec 2024
Morgan Stanley
Patrick Wood
55% 1-year accuracy
6 / 11 met price target
22%upside
$45
Overweight
Upgraded
2 Dec 2024
Barclays
Matt Miksic
64% 1-year accuracy
23 / 36 met price target
62%upside
$60
Overweight
Maintained
8 Nov 2024
Canaccord Genuity
William Plovanic
54% 1-year accuracy
25 / 46 met price target
51%upside
$56
Buy
Maintained
7 Nov 2024
Baird
Jeff Johnson
23% 1-year accuracy
3 / 13 met price target
0%upside
$37
Neutral
Maintained
7 Nov 2024

Financial journalist opinion

Based on 3 articles about TNDM published over the past 30 days

Positive
Zacks Investment Research
1 week ago
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Tandem Diabetes' t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Neutral
Business Wire
2 weeks ago
Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada
MARKHAM, Ontario--(BUSINESS WIRE)-- #TandemDiabetes--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump users can now access full compatibility with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. The t:slim X2 insulin pump with Control-IQ technology is the #1-rated automated insulin delivery (AID) system1, and now the first and only insulin pump in Canada th.
Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada
Positive
Zacks Investment Research
2 weeks ago
Reasons to Retain TNDM Stock in Your Portfolio for Now
Innovations and a robust international market expansion raise investors' optimism for Tandem Diabetes.
Reasons to Retain TNDM Stock in Your Portfolio for Now
Neutral
Business Wire
1 month ago
Tandem Diabetes Care Announces Upcoming Conference Presentations
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3, 2024 at 8:00am Eastern Time (5:00am Pacific Time), and Citi's 2024 Global Healthcare Conference on Wednesday, December 4, 2024 at 1:00pm Eastern Time (10:00am Pacific Time). The presentations wil.
Tandem Diabetes Care Announces Upcoming Conference Presentations
Positive
Zacks Investment Research
1 month ago
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
Tandem Diabetes' top and bottom lines outpace estimates in the third quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.
TNDM Q3 Earnings Beat, '24 Sales View Up, Stock Falls in Aftermarket
Neutral
Seeking Alpha
1 month ago
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript
Neutral
Zacks Investment Research
1 month ago
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say
Negative
Zacks Investment Research
1 month ago
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.38 per share a year ago.
Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Tops Revenue Estimates
Neutral
Business Wire
1 month ago
Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales guidance for the year ending December 31, 2024. Third Quarter 2024 Highlights Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023; worldwide non-GAAP sales(1) increased 25 percent to $242.9 million compared to third quarter 2023. Gr.
Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance
Neutral
Business Wire
1 month ago
Tandem Diabetes Care Announces Upcoming Conference Participation
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: UBS Global Healthcare Conference on Thursday, November 14, 2024 at 11:45am Eastern Time (8:45am Pacific Time), Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024 at 11:30am Eastern Time (8:30am Pacific Time), Jefferies London Healthcare.
Tandem Diabetes Care Announces Upcoming Conference Participation
Charts implemented using Lightweight Charts™